Priou Pascaline, Le Vaillant Marc, Meslier Nicole, Chollet Sylvaine, Pigeanne Thierry, Masson Philippe, Bizieux-Thaminy Acya, Humeau Marie-Pierre, Goupil François, Ducluzeau Pierre-Henri, Gagnadoux Frédéric
Département de Pneumologie, Université d'Angers, CHU, Angers, France.
INSERM U1063, Angers, France.
J Sleep Res. 2015 Aug;24(4):425-31. doi: 10.1111/jsr.12278. Epub 2015 Feb 19.
The purpose of this study was to determine whether the association between obstructive sleep apnea severity and glucose control differs between patients with newly diagnosed and untreated type 2 diabetes, and patients with known and treated type 2 diabetes. This multicentre cross-sectional study included 762 patients investigated by sleep recording for suspected obstructive sleep apnea, 497 of whom were previously diagnosed and treated for type 2 diabetes (treated diabetic patients), while 265 had no medical history of diabetes but had fasting blood glucose ≥126 mg dL(-1) and/or glycated haemoglobin (HbA1c ) ≥6.5% consistent with newly diagnosed type 2 diabetes (untreated diabetic patients). Multivariate regression analyses were performed to evaluate the independent association between HbA1c and obstructive sleep apnea severity in treated and untreated patients with diabetes. In untreated diabetic patients, HbA1c was positively associated with apnea-hypopnea index (P = 0.0007) and 3% oxygen desaturation index (P = 0.0016) after adjustment for age, gender, body mass index, alcohol habits, metabolic dyslipidaemia, hypertension, statin use and study site. The adjusted mean value of HbA1c increased from 6.68% in the lowest quartile of the apnea-hypopnea index (<17) to 7.20% in the highest quartile of the apnea-hypopnea index (>61; P = 0.033 for linear trend). In treated patients with diabetes, HbA1c was associated with non-sleep variables, including age, metabolic dyslipidaemia and insulin use, but not with obstructive sleep apnea severity. Obstructive sleep apnea may adversely affect glucose control in patients with newly diagnosed and untreated type 2 diabetes, but may have a limited impact in patients with overt type 2 diabetes receiving anti-diabetic medications.
本研究的目的是确定阻塞性睡眠呼吸暂停严重程度与血糖控制之间的关联在新诊断且未治疗的2型糖尿病患者和已知且已治疗的2型糖尿病患者中是否存在差异。这项多中心横断面研究纳入了762例因疑似阻塞性睡眠呼吸暂停而接受睡眠记录检查的患者,其中497例既往已被诊断并接受2型糖尿病治疗(已治疗糖尿病患者),而265例无糖尿病病史,但空腹血糖≥126 mg dL⁻¹和/或糖化血红蛋白(HbA1c)≥6.5%,符合新诊断的2型糖尿病(未治疗糖尿病患者)。进行多变量回归分析以评估已治疗和未治疗糖尿病患者中HbA1c与阻塞性睡眠呼吸暂停严重程度之间的独立关联。在未治疗糖尿病患者中,校正年龄、性别、体重指数、饮酒习惯、代谢性血脂异常、高血压、他汀类药物使用情况和研究地点后,HbA1c与呼吸暂停低通气指数(P = 0.0007)和3%氧饱和度下降指数(P = 0.0016)呈正相关。HbA1c的校正均值从呼吸暂停低通气指数最低四分位数(<17)时的6.68%增加至呼吸暂停低通气指数最高四分位数(>61)时的7.20%(线性趋势P = 0.033)。在已治疗糖尿病患者中,HbA1c与非睡眠变量相关,包括年龄、代谢性血脂异常和胰岛素使用情况,但与阻塞性睡眠呼吸暂停严重程度无关。阻塞性睡眠呼吸暂停可能对新诊断且未治疗的2型糖尿病患者的血糖控制产生不利影响,但对接受抗糖尿病药物治疗的显性2型糖尿病患者的影响可能有限。